Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

The vaccination regimen was safe over time, and both humoral and cellular immunity persisted in the vaccinated population aged 3-18 years, 5-7 months after receiving the heterologous SOBERANA® 02 and SOBERANA® Plus vaccine schedule.Trial registry: https://rpcec.sld.cu/trials/RPCEC00000374-En.

Authors

Institutions

Publication Details

Journal
Vaccine X
Published
2024-12-06
DOI
https://doi.org/10.1016/j.jvacx.2024.100595
Citations
1
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

Enrique Noa-Romero, Meiby Rodríguez-González, Ariel Palenzuela-Díaz, Rinaldo Puga-Gómez et al.
1 citations
Vaccine X
SARS-CoV-2 and COVID-19 Research
0.39
article

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

Enrique Noa-Romero, Meiby Rodríguez-González, Ariel Palenzuela-Díaz, Rinaldo Puga-Gómez, Darielys Santana-Mederos, Laura Rodríguez-Noda, Arilia García-López, Dagmar García-Rivera, Rocmira Pérez-Nicado, Sonsire Fernández-Castillo, Marisel Martínez-Pérez, Otto Cruz-Sui, Yury Valdés-Balbín, Vicente Vérez-Bencomo, Belinda Sánchez-Ramírez, Yanet Climent-Ruíz, Yariset Ricardo-Delgado, Tays Hernández-García, Beatriz Paredes-Moreno, Carmen Valenzuela Silva
article en
1 citations

Abstract

The vaccination regimen was safe over time, and both humoral and cellular immunity persisted in the vaccinated population aged 3-18 years, 5-7 months after receiving the heterologous SOBERANA® 02 and SOBERANA® Plus vaccine schedule.Trial registry: https://rpcec.sld.cu/trials/RPCEC00000374-En.

Vaccine XVol. 22
Center of Molecular Immunology (Cuba) (CU), Cuban Neuroscience Center (CU), Finlay Institute (CU), Hospital Oncológico Docente "Conrado Benítez García" (CU)
Ministerio de Ciencia, Tecnología y Medio Ambiente
Zero hunger
Openalex Percentile: Top 34%
SARS-CoV-2 and COVID-19 Research
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.